Paul Spence

Mr. Spence brings more than 20 years of commercial leadership experience in the pharmaceutical industry, with a strong track record of launching and driving growth of innovative therapies across multiple therapeutic areas. He joined Halozyme in 2025 as Chief Commercial Officer and is responsible for leading the company’s commercial strategy, including XYOSTED® and Hylenex® sales, marketing, market access, and patient engagement.

Prior to joining Halozyme, Mr. Spence served as Chief Commercial Officer at Optinose. He previously held senior leadership roles at Nestlé Health Sciences, including Senior Vice President and U.S. Pharma Chief Commercial Officer, where he led the Aimmune Gastrointestinal and Food Allergy businesses from 2020 to 2022, and Vice President, U.S. Commercial from 2016 to 2019. Earlier in his career, Mr. Spence held commercial roles of increasing responsibility at Boehringer-Ingelheim Pharmaceuticals, Sanofi-Aventis, and Bristol-Myers Squibb, where he developed deep expertise in strategic brand management, sales force effectiveness, and market development.

Mr. Spence earned a Bachelor of Science in Finance from the Pennsylvania State University and a Master of Business Administration from Villanova University.